Ventrus Biosciences Balance Sheet - Annual (NASDAQ:ASMB)

Add to My Stocks
$44.18 $1.53 (3.35%) ASMB stock closing price Jun 22, 2018 (Closing)

The financial analysis of a company involves interpreting the income statement, balance sheet and cash flow statements of the company to draw insights like we've done in our Ventrus Biosciences stock analysis. How cash on hand has increased or decreased is one of the many indicators used while undertaking the Ventrus Biosciences stock analysis, and provides insights into the firm's financial performance. A company releases its balance sheet every year along with its annual results. Apart from analyzing Ventrus Biosciences revenue Ventrus Biosciences operating cash flow, one needs to check balance sheet items like cash, fixed assets and debt. The Ventrus Biosciences balance sheet for 2017 shows cash on hand of $82.03M. The company has a debt to equity ratio of 0.

View latest 10 year balance sheet data to check Ventrus Biosciences financial performance.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec201720162015201420132012201120102009
Cash82.03M28.57M27.1M29.09M27.06M20.48M36.97M14.57M-
Marketable Securities37.91M24.38M40.55M------
Receivables2.27M--------
Inventory---------
Raw Materials---------
Work In Progress---------
Finished Goods---------
Notes Receivable---------
Other Current Assets---------
Total Current Assets
123.11M53.57M68.36M29.21M27.12M20.54M37.03M14.58M-
Property Plant & Equipment1.27M--------
Accumulated Depreciation---------
Net Property Plant & Equipment
---------
Investment & Advances3.34M2.43M23.39M------
Other Non-Current Assets---------
Deferred Charges---------
Intangibles41.63M41.63M41.63M41.73M-----
Deposits & Other Assets---------
Total Assets
169.3M98.11M133.74M71.22M27.13M20.55M37.04M14.61M-
Notes Payable---------
Accounts Payable2.12M2.36M1.36M-2.61M1.84M2.34M--
Current Portion Long-Term Debt-------1.21M-
Current Portion Capital Leases---------
Accrued Expenses6.13M4.75M2.03M------
Income Taxes Payable---------
Other Current Liabilities5.22M--------
Total Current Liabilities
13.49M7.12M3.4M1.05M2.63M2.74M2.51M1.71M-
Mortgages---------
Deferred Taxes/Income42.69M11.11M11.6M11.6M-----
Convertible Debt---------
Long-Term Debt-------1.27M-
Non-Current Capital Leases---------
Other Long-Term Liabilities---------
Total Liabilities
56.18M18.24M15M12.65M2.63M2.74M2.51M2.99M-
Minority Interest---------
Preferred Stock---------
Common Stock Net---------
Capital Surplus364.52M288.68M283.51M194.07M135.82M110.11M102.04M44.8M-
Retained Earnings-251.03M-208.22M-163.96M-135.51M-111.72M-92.31M-67.52M-33.18M-
Treasury Stock---------
Other Liabilities-0.39M-0.6M-0.82M------
Shareholders Equity113.11M79.87M118.74M58.57M24.49M17.81M34.53M11.62M-
Total Liabilities & Shareholders Equity169.3M98.11M133.74M71.22M27.13M20.55M37.04M14.61M-
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Most investors just check the Ventrus Biosciences stock price, and Ventrus Biosciences historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Ventrus Biosciences PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: An asset is a resource that a corporation like Ventrus Biosciences owns and has economic value. The two major types of assets are: fixed assets like real estate, plant and machinery and current assets like cash, marketable securities and inventory. The total asset value for ASMB stock as of 2017 is $169.3M. Its easy to associate the term with manufacturing companies, which invest a lot in factories and equipment. However, the same cannot be said about tech stocks.
  • Liabilities include short term loans and long term loans availed by the company to fund its business operations. ASMB stock had total liabilities of $56.18M for the year 2017.

Ventrus Biosciences Balance Sheet - Key Ratios

Current ratio
9.3
Debt to equity ratio
0
Asset turnover ratio
0.09
Receivables turnover
8.46
Price to book ratio
11.55